Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are 18 years of age or older.
• You are planned to receive an approved CAR-T cell therapy targeting CD19 (specifically axi-cel or liso-cel).
• Your doctor has decided you need "bridging therapy" — treatment given while you wait for your CAR-T cell therapy.
• You have been diagnosed with a specific type of aggressive B-cell lymphoma (including DLBCL, transformed follicular lymphoma, PMBCL, or certain high-grade B-cell lymphomas) that has come back or stopped responding to treatment after at least one previous combination treatment.
• Your cancer can be detected and measured on scans (PET-CT, CT, or MRI).
• You are reasonably active and able to care for yourself, with only limited restrictions on daily activities (confirm with trial site).
• Enough time has passed since your last cancer treatment — the exact amount of time depends on what type of treatment you received (ranging from 14 days to 60 days).
• Your blood counts, liver, and kidney functions are at acceptable levels as measured by blood tests.
• If you are a woman who could become pregnant, you must have a negative pregnancy test, or be confirmed post-menopausal or surgically sterile.
• If you or your partner could become pregnant, you must agree to use highly effective contraception during the study.
• You are able to understand and sign an informed consent form agreeing to take part.

Who may not be able to join:

• You have previously received any treatment that targets CD19, including the study drug (lonca) or a CD19 CAR-T therapy before.
• You are enrolled in another trial using an experimental CAR-T product.
• You had major surgery within the 4 weeks before starting the study treatment.
• You have a history of a bleeding disorder (such as von Willebrand's disease or haemophilia) or are currently experiencing active bleeding.
• You have severe chronic liver disease (classified as Child-Pugh class C).
• You are pregnant, breastfeeding, or planning to become pregnant during the study.
• You have active graft-versus-host disease (a complication that can occur after a transplant).
• You have a condition called post-transplantation lymphoproliferative disorder.
• You have an active autoimmune disease that, in your doctor's opinion, could affect your safety or ability to participate.
• You have another cancer diagnosis that your doctor believes could affect your safety or participation in the trial.
• Your lymphoma has spread to your brain or central nervous system.
• You have serious heart problems, including severe heart failure, recent heart attack (within 6 months), dangerous irregular heartbeats, or certain abnormalities on a heart tracing (ECG) (confirm with trial site).
• You have severe lung disease, uncontrolled diabetes, or a severely weakened immune system.
• You have an active infection (bacterial, viral, fungal, or other) that requires treatment at the time of screening.
• You are living with HIV.
• You have an active hepatitis B infection (certain hepatitis B cases may still be considered — confirm with trial site); active hepatitis C may be considered if you are not currently being treated for it and your liver function meets the required levels.
• You have had a severe allergic reaction to a CD19-targeted antibody or to the study drug or any of its ingredients.
• You are currently taking certain medications that are not allowed in this study and are unable to stop them for the required period beforehand (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.